In accordance with section 27a of Consolidated Act about Securities Trading
etc., we hereby issue a complete list of NeuroSearch announcements in 2009 and
in January - March 2010. All announcements are available under the IR section
of our homepage www.neurosearch.com.

Date No. Heading

29.01.2009 01-09 NeuroSearch announce an expansion to their existing alliance
with GlaxoSmithKline

11.02.2009 02-09 NeuroSearch announces results from Phase II studies of ABT-894
in diabetic neuropathic pain

17.02.2009 03-09 NeuroSearch announces drug discovery and development alliance
with Eli Lilly and Company

23.02.2009 04-09 NeuroSearch announces the results of Phase II Proof of Concept
studies with NS2359 in depression

02.03.2009 05-09 NeuroSearch regains global rights to ACR16

03.03.2009 06-09 NeuroSearch has issued 530,745 new shares in a directed
offering subscribed by Eli Lilly and Company in connection with the signing of
a drug discovery and development alliance

04.03.2009 07-09 NeuroSearch A/S Financial Statements 2008

04.03.2009 08-09 List of NeuroSearch announcements in 2008 and in January -
March 2009

31.03.2009 09-09 NeuroSearch successfully completes patient recruitment in
MermaiHD, a pivotal Phase III study of ACR16 in Huntington's disease - and
updates on other pipeline news

31.03.2009 10-09 NeuroSearch A/S' share capital and voting rights

14.04.2009 11-09 Notice convening Annual General Meeting in NeuroSearch A/S

29.04.2009 12-09 NeuroSearch A/S - Interim report for Q1 2009

29.04.2009 13-09 Report on Ordinary General Meeting held in NeuroSearch A/S

01.05.2009 14-09 Notice convening Extraordinary General Meeting in NeuroSearch
A/S

07.05.2009 15-09 NeuroSearch establishes credit facility of DKK 50 million to
finance a programme for the purchase of own shares to hedge milestone payments

18.05.2009 16-09 NeuroSearch A/S - Share purchase programme

20.05.2009 17-09 Report on Extraordinary General Meeting held in NeuroSearch A/S

20.05.2009 18-09 NeuroSearch issues warrants to the members of the Board of
Directors, the Executive Management and other employees

25.05.2009 19-09 NeuroSearch A/S - Share purchase programme - Status update

02.06.2009 20-09 NeuroSearch A/S - Share purchase programme - Status update

08.06.2009 21-09 NeuroSearch successfully completes End of Phase II meeting
with the FDA for tesofensine, a treatment for obesity

08.06.2009 22-09 NeuroSearch A/S - Share purchase programme - Status update

15.06.2009 23-09 NeuroSearch A/S - Share purchase programme - Status update

22.06.2009 24-09 NeuroSearch A/S - Share purchase programme - Status update

29.06.2009 25-09 NeuroSearch A/S - Share purchase programme - Status update

06.07.2009 26-09 NeuroSearch A/S - Share purchase programme - Status update

13.07.2009 27-09 NeuroSearch A/S - Share purchase programme - Status update

20.07.2009 28-09 NeuroSearch A/S - Share purchase programme - Status update

27.07.2009 29-09 NeuroSearch A/S - Share purchase programme - Status update

03.08.2009 30-09 NeuroSearch A/S - Share purchase programme - Status update

04.08.2009 31-09 NeuroSearch successfully advances NSD-721 for treatment of
social anxiety disorder and receives EUR 5 million in equity financing under
the alliance with GlaxoSmithKline

10.08.2009 32-09 NeuroSearch A/S - Share purchase programme - Status update

10.08.2009 32-08 Correction: NeuroSearch A/S - Share purchase programme -
Status update

13.08.2009 33-09 NeuroSearch has issued 345,238 new shares in a directed market
offering subscribed by GlaxoSmithKline upon exercise of option to issue shares
under the alliance

17.08.2009 34-09 NeuroSearch announces drug discovery and drug development
alliance with Janssen Pharmaceutica NV

17.08.2009 35-09 NeuroSearch A/S - Share purchase programme - Status update

20.08.2009 36-09 NeuroSearch announces revised timetable for the issue of new
shares to Johnson & Johnson Development Corporation

24.08.2009 37-09 NeuroSearch A/S - Share purchase programme - Status update

25.08.2009 38-09 NeuroSearch has issued 618,562 new shares in a directed market
offering subscribed by Johnson & Johnson Development Corporation in connection
with the signing of a drug discovery and drug development alliance

26.08.2009 39-09 NeuroSearch A/S - Interim report for the first half-year of
2009

27.08.2009 40-09 Notice convening Extraordinary General Meeting in NeuroSearch
A/S

31.08.2009 41-09 NeuroSearch A/S - Share purchase programme - Status update

31.08.2009 42-09 NeuroSearch A/S' share capital and voting rights

03.09.2009 43-09 NeuroSearch announces the advance of NsGene's Neublastin into
Phase I clinical development as a novel treatment for neuropathic pain

07.09.2009 44-09 Report on Extraordinary General Meeting held in NeuroSearch A/S

07.09.2009 45-09 NeuroSearch A/S - Share purchase programme - Status update

07.09.2009 46-09 Notice convening Extraordinary General Meeting in NeuroSearch
A/S

14.09.2009 47-09 NeuroSearch A/S - Share purchase programme - Status update

18.09.2009 48-09 Report on Extraordinary General Meeting held in NeuroSearch A/S

21.09.2009 49-09 NeuroSearch A/S - Share purchase programme - Status update

28.09.2009 50-09 NeuroSearch A/S - Share purchase programme - Status update

05.10.2009 51-09 NeuroSearch A/S - Share purchase programme - Status update

08.10.2009 52-09 NeuroSearch initiates a clinical study with ACR325 for the
treatment of dyskinesias (involuntary movements) in Parkinson's disease

12.10.2009 53-09 NeuroSearch A/S - Share purchase programme - Status update

19.10.2009 54-09 NeuroSearch announces revised financial calendar for 2009 and
the company's financial calendar for 2010

19.10.2009 55-09 NeuroSearch A/S announces discontinuation of share purchase
programme

19.10.2009 56-09 NeuroSearch today publishes an offering circular in connection
with a rights issue of up to a maximum of 7,387,641 new shares with a nominal
value of DKK 20 each at DKK 60 per share (the "Offering")

11.11.2009 57-09 NeuroSearch A/S completes preemptive rights issue

16.11.2009 58-09 NeuroSearch A/S - Interim report for Q3 2009

16.11.2009 59-09 OppenheimerFunds, Inc.'s share ownership of NeuroSearch has
been diluted to less than 5% in connection with the completion of the company's
share issue

30.11.2009 60-09 NeuroSearch A/S' share capital and voting rights

14.12.2009 61-09 NeuroSearch A/S announces end of stabilisation period in
connection with the rights issue completed November 2009

03.02.2010 01-10 NeuroSearch announces positive top-line results from Phase III
Huntexil® study in Huntington's disease (the MermaiHD study)

11.02.2010 02-10 NeuroSearch presents additional data from the MermaiHD study
with Huntexil® at the 5th Annual CHDI Conference on Huntington's disease

08.03.2010 03-10 NeuroSearch announces new findings from the MermaiHD Phase III
study supporting potential disease modifying properties of Huntexil®

10.03.2010 04-10 NeuroSearch - Financial statements 2009

Flemming Pedersen
CEO

Contact person:
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4017 5103

About NeuroSearch - Company profile
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen A/S. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform, focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and
GlaxoSmithKline, and licence collaboration with Abbott. The drug pipeline
comprises eight clinical (Phase I-III) development programmes: Huntexil®
(pridopidine) for Huntington's disease (Phase III), tesofensine for obesity
(ready for Phase III), ABT-894 for ADHD (Phase II) in partnership with Abbott,
ACR343 for schizophrenia (ready for Phase II), ACR325 to treat dyskinesias in
Parkinson's disease (Phase Ib), ABT-560 for the treatment of cognitive
dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for
anxiety/depression (Phase I) and NSD-721 for social anxiety disorder (Phase I)
in partnership with GSK. In addition, NeuroSearch has a broad portfolio of
preclinical drug candidates and holds equity interests in several biotech
companies.